๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
NCT07657403Brain Neoplasms, Eloquent Area Brain Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
200
Beijing
2025-11-01
Not yet open
A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure
NCT07230145Heart Failure
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 1
48
Beijing
2025-11
Not yet open
Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity
NCT07241338Hypertension
Jing Liu
Phase 4
104
Beijing
2025-11
Not yet open
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Not yet open
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
NCT06468436Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine
Peking University First Hospital
Not applicable
1,508
Beijing, Tianjin
2025-11
Not yet open
Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial
NCT07061184Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM), N of 1 Study Design, Efficacy and Safety
Peking Union Medical College Hospital
Phase 4
50
Beijing
2025-11
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
NCT07172347Non-segmental Vitiligo
Jiangsu vcare pharmaceutical technology co., LTD
Phase 2
120
Beijing
2025-10-31
Recruiting
Evaluation of the Safety and Effectiveness of CHORDSยฎ Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
NCT07110103SCLC, SCLC, Extensive Stage
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
20
Beijing, Chongqing
2025-10-31
Recruiting
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT07208591Acute Respiratory Distress Syndrome (ARDS)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Not yet open
An Exploratory Study of Golidocitinib in Adult Patients With ITP
NCT07196163Immune Thrombocytopenia (ITP)
Peking University People's Hospital
Phase 1/2
138
Beijing
2025-10-30
Not yet open
An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease
NCT06836180Alzheimer Disease
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1
40
Beijing
2025-10-30
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
Affiliated Hospital of Nantong University
Not applicable
258
Bengbu, Beijing, Hangzhou
2025-10-30
Recruiting
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
NCT07246031Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
BioPhoenix Co., Ltd.
Phase 2
50
Beijing, Wuhan
2025-10-29
Recruiting
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
NCT07327840Lipoprotein Disorder
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changchun, Changde, Changsha, Chengdu, Chongqing, Dali
2025-10-29
Recruiting
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
NCT07250269Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
9
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Recruiting
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
NCT07192939IPF and PPF
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
270
Beijing
2025-10-29
Active, closed
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT07220109Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Recruiting
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
NCT07140393Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
120
Beijing
2025-10-28
Recruiting
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
NCT07120282Lung Cancer (NSCLC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
108
Beijing
2025-10-28
Recruiting
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants
NCT07237464Cancer Cachexia (CC), Cancer Cachexia, Cancer Cachexia Syndrome
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
36
Beijing
2025-10-28
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Beijing, Xi'an
2025-10-28
Active, closed
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407Non-cystic Fibrosis Bronchiectasis
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT07082842Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.
Phase 3
472
Beijing
2025-10-27
Recruiting
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
NCT07499700Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
Bio-Thera Solutions
Phase 2/3
192
Beijing
2025-10-26
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
NCT07187687Intracerebral Hemorrhage
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Recruiting
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
NCT07175155Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
FARAPULSEโ„ข Pulsed Field Ablation System
NCT06762717Paroxysmal AF
Boston Scientific Corporation
Observational
500
Beijing
2025-10-23
Recruiting
The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea
NCT07580950Functional Hypothalamic Amenorrhea
Peking Union Medical College Hospital
Phase 4
210
Beijing
2025-10-22
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
NCT07179484Gastroesophageal Junction Adenocarcinoma
Beijing GoBroad Hospital
Observational
20
Beijing
2025-10-22
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
NCT07208136Advanced Solid Tumors
Jemincare
Phase 1
102
Beijing
2025-10-22
Recruiting
Complex Arrhythmia Registry
NCT07024927Atrial Fibrillation (AF), Ventricular Tachycardia (VT)
Beijing Anzhen Hospital
Observational
4,000
Beijing
2025-10-21
Recruiting
Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects
NCT07301203Healthy, Healthy Participants
Beijing Tide Pharmaceutical Co., Ltd
Phase 1
90
Beijing
2025-10-21
Recruiting
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
NCT07209787Rectal Cancer
Beijing Chao Yang Hospital
Phase 4
966
Beijing
2025-10-21
Recruiting
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT07259590Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia
NCT07208357Fibromyalgia, Pregabalin, Duloxetine, Pain
Beijing Tiantan Hospital
Not applicable
384
Beijing
2025-10-20
Recruiting
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
NCT07585981IgA Glomerulonephritis
Chinese PLA General Hospital
Observational
30
Beijing
2025-10-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenstrรถm Macroglobulinemia
NCT07169331Waldenstrรถm's Macroglobulinemia
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
NCT07231081Solid Tumors
Tcelltech Inc.
Phase 1
85
Beijing
2025-10-16
Recruiting
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
NCT07209345Post-craniotomy, Pain
Beijing Tiantan Hospital
Not applicable
216
Beijing
2025-10-15
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
188
Beijing
2025-10-15
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
NCT07240454Chronic Subdural Hematoma
Tao Liu
Not applicable
143
Beijing, Tianjin
2025-10-15
Recruiting
Ventricular Tachycardia๏ผšA Registry Study
NCT07149701Ventricular Tachycardia (VT), Structural Heart Disease
Beijing Anzhen Hospital
Observational
1,000
Beijing
2025-10-14
Recruiting
Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy
NCT07202559Pancreatitis, Chronic, Pancreatitis, Acute, Pancreatic Duct Stones
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
By invitation
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
NCT07330440Genital Herpes
Changchun BCHT Biotechnology Co.
Phase 1
144
Beijing
2025-10-13
Recruiting
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT07129343Von Willebrand Disease (VWD)
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Balloon Guide Catheter to Optimize Outcomes in Stroke Thrombectomy of the Internal Carotid Artery
NCT07192029Stroke
Xuanwu Hospital, Beijing
Not applicable
364
Fuzhou, Zhangzhou, Beijing
2025-10-12
Recruiting
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
NCT07308548NAFLD (Non-alcoholic Fatty Liver Disease)
Hinova Pharmaceuticals Inc.
Phase 2
80
Beijing, Chengdu
2025-10-11
Not yet open
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
NCT07190716Single Ascending Dose, Healthy Subjects
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
36
Beijing
2025-10-10
Not yet open
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
NCT07200921Hypertensive Intracerebral Hemorrhage, Cerebral Small Vessel Diseases
Beijing Tiantan Hospital
Phase 2
1,950
Beijing
2025-10-10
Recruiting
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
130
Fuyang, Beijing, Ulanhot, รœrรผmqi
2025-10-10
Recruiting
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
NCT07040072HNSCC
Beijing Tongren Hospital
Phase 1
10
Beijing
2025-10-09
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
Merck Sharp & Dohme LLC
Phase 2
182
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, รœrรผmqi, Linhai
2025-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
Light and Anesthesia
NCT07517484Light, Anesthesia, Sedation
Peking University People's Hospital
Not applicable
66
Beijing
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Active, closed
Early-Life Strategies for Preventing Obesity in Preschool-aged Children
NCT07117149Childhood Obesity Prevention
Peking University
Not applicable
980
Beijing
2025-10-02
Recruiting
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
NCT07488728EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir
Beijing Children's Hospital
Not applicable
80
Beijing
2025-10-01
Recruiting
Effects of Tracheostomy Decannulation on Respiratory Function
NCT07191509Tracheostomy Decannulation
Capital Medical University
Observational
100
Beijing
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
Recruiting
Urokinase for Thrombolysis in Acute Ischemic Stroke
NCT07047326Acute Ischemic Stroke
Capital Medical University
Not applicable
24
Beijing, Handan
2025-10-01
Active, closed
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
NCT07437859Primary Liver Cancer
Peking Union Medical College Hospital
Observational
60
Beijing
2025-10-01
Not yet open
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
NCT07018063Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
zhoujing
Phase 2
35
Beijing
2025-10-01
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Active, closed
TNF-ฮฑ Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.
NCT07176754Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Peking University Third Hospital
Not applicable
208
Beijing
2025-10-01
Not yet open
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
NCT07182708NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
62
Beijing
2025-10-01
Not yet open
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
NCT06556862HR+/HER2- Advanced Breast Cancer
Beijing 302 Hospital
Phase 2
155
Beijing
2025-10-01
Recruiting
SV With TTPEE Measurement Predicts Upper Airway Patency in Prolonged Tracheostomy Patients
NCT07107243Tracheostomy
Capital Medical University
Not applicable
300
Hunan, Guangxi, Beijing, Jilin City, Henan
2025-10-01
Not yet open
Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes
NCT07198932Type 2 Diabetes
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Not yet open
Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke
NCT07197606Ischemic Stroke
Shanghai IxCell Biotechnology Co., LTD
Phase 2
86
Beijing
2025-10-01
Active, closed
Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging
NCT07340762HCM - Hypertrophic Cardiomyopathy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
20,000
Beijing
2025-10-01
Recruiting
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
NCT07200141Locally Advanced Rectal Adenocarcinoma
Peking Union Medical College Hospital
Phase 2
156
Beijing
2025-10-01
Active, closed
Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer
NCT07735858Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-10-01
Recruiting
Time to Ambulation After ProGlide Closure
NCT07179536Femoral Access Site Closure, Ambulation, Vascular Access Complication, Vascular Access Site Management
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Beijing
2025-10-01
Rows per page Showing 1501–1600 of 5484
Previous 14 15 16 17 18 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=16

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.